Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)

Next Previous
Trial Profile

Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1358894 (Primary) ; Dabigatran etexilate; Rosuvastatin
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 09 Jan 2020 Status changed from active, no longer recruiting to completed.
  • 18 Nov 2019 Planned End Date changed from 15 Nov 2019 to 5 Dec 2019.
  • 18 Nov 2019 Planned primary completion date changed from 15 Nov 2019 to 5 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top